If you develop-or are considering developing-herbal dietary supplements for men's prostate health, you've likely faced a frustrating reality:

Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) is dominated by long-term pelvic pain, inflammation, and quality‑of‑life burden.

Benign prostatic hyperplasia (BPH) is driven by progressive urinary symptoms tied to gland/stroma growth and age‑related endocrine changes.

They look different clinically. Yet patients often overlap, conventional options can be incomplete, and recurrence plus side effects remain real-world issues. That's why the Traditional Chinese Medicine (TCM) idea of "treating different diseases with the same approach" (异病同治) is attracting renewed interest-especially when it can be explored with modern evidence tools.

This article translates and reframes a research work that applied network pharmacology and molecular docking to investigate how Sanhe Decoction (三核汤) may exert shared therapeutic effects across CP/CPPS and BPH-and what that means for evidence‑informed botanical supplement development.

 

1) Why CP/CPPS and BPH Matter for Prostate-Health Product Development

CP/CPPS (NIH Category III prostatitis)

CP/CPPS is the most common prostatitis type (often cited as ~95% of prostatitis cases). It typically features:

persistent pelvic region pain as a core symptom

lower urinary tract symptoms

sexual dysfunction

psychological stress, anxiety, or depressive features

Its mechanisms are multifactorial, commonly involving neuroendocrine imbalance, pelvic floor dysfunction, and immune‑inflammatory responses.

BPH

BPH presents mainly as progressive lower urinary tract symptoms. Pathologically, it involves:

hyperplasia of prostate stroma and glands

bladder outlet obstruction

close association with aging, endocrine/hormonal shifts, inflammation, and growth-factor dysregulation

The overlap-and the opportunity

Although treatment strategies differ (e.g., pain management and neuromodulation for CP/CPPS vs. obstruction relief via 5α‑reductase inhibitors or surgery for BPH), both conditions share something important: chronic inflammatory microenvironment and frequent comorbidity patterns. This overlap suggests shared biological "control knobs"-valuable for designing multi-target botanical formulas.

 

Herb Cistanche Botanical Formulas

 

 

2) The TCM Framework: "One Mechanism, Multiple Diseases"

In TCM, "treat different diseases with the same method" means treatment is chosen based on the underlying pattern (pathogenesis) rather than the disease name.

For CP/CPPS and BPH, TCM practice often recognizes shared patterns such as:

kidney deficiency (肾虚)

damp‑heat (湿热)

qi stagnation (气滞)

blood stasis (血瘀)

Sanhe Decoction is a 14-herb formula traditionally used to soften hardness and dissipate masses, regulate qi and blood, dispel dampness, support liver and kidney function, and address complex chronic patterns.

The practical question for product developers is:
Can we map these traditional ideas to modern molecular targets and pathways in a way that supports rational supplement design?

 

 

How To Take The Herb Cistanche Formula For Improving Kidney And Prostate Function

3) Study Design (Modern Methods Applied to a Classical Formula)

The research used a typical "computational + bioinformatics" systems pharmacology workflow:

Step A - Identify candidate compounds and targets

Databases used included:

TCMSP, TCMID, HERB, PubChem, SwissTargetPrediction
Compounds were screened by:

Oral bioavailability (OB) ≥ 30%

Drug-likeness (DL) ≥ 0.18

Targets were standardized via UniProt.

Step B - Collect disease targets for CP/CPPS and BPH

Disease targets were assembled from:

DisGeNET, GeneCards, OMIM, TTD

Step C - Intersect "formula targets" with "disease targets"

Venn analysis identified shared targets between:

Sanhe Decoction vs CP/CPPS

Sanhe Decoction vs BPH

and the intersection across all three

Step D - Protein-protein interaction (PPI) + network topology

STRING for PPI network

Cytoscape + topological metrics (e.g., Degree) to find hub targets and key compounds

GO/KEGG enrichment to interpret biological meaning

CB‑dock2 for molecular docking (binding energy estimation + visualization)

 

4) Key Results: Multi-Component, Multi-Target, Multi-Pathway

4.1 Active components and targets

212 candidate active compounds were collected for the formula

951 nonredundant targets were predicted/compiled for these compounds

4.2 Disease targets and shared therapeutic targets

5,512 CP/CPPS-associated targets

1,137 BPH-associated targets

240 shared targets were identified as potential therapeutic nodes across CP/CPPS + BPH + the formula

This is the core rationale for "异病同治" from a network perspective: different diseases, but a shared therapeutic target set.

 

5) Core Bioactive Compounds Worth Noting (for Supplement & Ingredient Strategy)

Network analysis highlighted these as top‑ranked compounds (high Degree, strong network relevance):

Quercetin

Kaempferol

Nootkatone

Stigmasterol

Isorhamnetin

From a product perspective, these are not random: they are widely discussed plant bioactives with plausible anti‑inflammatory, antioxidant, endocrine‑modulating, and signal‑pathway effects-exactly the kind of "multi-hit" profile many prostate‑health supplement formulations aim to achieve.

 

6) Core Targets (Hub Nodes) That May Explain Shared Benefits

Top 5 hub targets in the PPI network were:

TP53

SRC

AKT1

ESR1

STAT3

Why these matter for developers:

STAT3 / AKT1 / SRC frequently appear in inflammation, survival signaling, and proliferation networks.

ESR1 links endocrine regulation and inflammation‑pain modulation.

TP53 relates to cell cycle, apoptosis, and senescence-relevant for tissue remodeling.

In other words: the hub list aligns with a model in which chronic inflammation and growth/survival signaling contribute to both CP/CPPS symptom persistence and BPH progression.

 

7) GO & KEGG Enrichment: What Biological "Jobs" Are Being Modulated?

GO enrichment highlights

Enrichment suggested involvement in processes such as:

epithelial cell proliferation and its regulation

apoptosis and cell death regulation

responses to bacterial molecules/LPS

response to steroid hormones

inflammatory signaling and cytokine-related functions

membrane microdomains (rafts/caveolae), vesicle lumens, transcriptional regulatory complexes

KEGG pathway highlights (269 pathways identified)

High-ranking pathways included:

AGE–RAGE signaling pathway in diabetic complications

Chemical carcinogenesis-receptor activation

PI3K–AKT signaling pathway

Proteoglycans in cancer

plus others linked to metabolic disease, cardiovascular contexts, viral infection, and cancer‑related signaling

For supplement innovation, the implication is not "this is a cancer drug," but rather that the formula's network touches high‑centrality signaling pathways that commonly govern inflammation, oxidative stress, endocrine response, and cellular growth control.

 

8) Molecular Docking: Do the Compounds "Fit" the Targets?

Docking focused on the five hub targets (TP53, SRC, AKT1, ESR1, STAT3) and the five core compounds (quercetin, kaempferol, nootkatone, stigmasterol, isorhamnetin).

Key reported docking outcomes:

All core compound–target binding energies were < −5.0 kcal/mol, interpreted as strong binding activity in this docking context.

Best pairs included:

quercetin–ESR1: −8.6 kcal/mol

stigmasterol–SRC: −9.9 kcal/mol

isorhamnetin–STAT3: −8.6 kcal/mol

kaempferol–AKT1: −8.3 kcal/mol

For developers: docking is not clinical proof, but it provides a mechanistic plausibility layer useful for R&D storytelling, hypothesis generation, and prioritizing compounds for experimental validation.

 

9) What This Means for Building a Prostate-Health Botanical Supplement (Practical Takeaways)

If you're choosing ingredients or building a formula strategy, this study supports several actionable principles:

Design for shared biology, not just disease labels
CP/CPPS and BPH overlap in inflammatory microenvironment and key pathways; a multi-target formula may reasonably aim at shared nodes.

Prioritize compounds with network centrality + plausible pathway coverage
Flavonoids and phytosterols often appear as high‑connectivity compounds in network models.

Build an evidence ladder

Network pharmacology → suggests targets/pathways

Docking → suggests binding plausibility

Cell/animal models → confirm pathway modulation (e.g., PI3K‑AKT, STAT3, AGE‑RAGE)

Human studies → validate outcomes and safety

Stay honest about limits
The study itself notes that docking validates binding potential but lacks direct experimental verification in cellular/animal models for key axes like PI3K‑AKT and STAT3. That transparency is valuable-and should be mirrored in responsible marketing.

 

 

10) Where Cistanche Fits in a Prostate-Health Conversation

For those building a product line, it can be useful to pair a mechanistic framework (multi-target inflammation + endocrine signaling) with botanicals that are already popular in men's health positioning.

One herb that is frequently discussed in men's wellness markets is Cistanche. If you want a consumer-friendly angle for education content (while keeping claims compliant and responsible), you can reference it as part of a broader prostate-health lifestyle + botanical support narrative.

You can read more here: Cistanche - "Say Goodbye to Prostate Problems with Cistanche" (link provided):
https://www.xjcistanche.com/news/say-goodbye-to-prostate-problems-with-cistanch-83534746.html

(Note: as with any botanical, positioning should be aligned with your local regulatory framework and supported by appropriate substantiation.)

 

Conclusion

Using network pharmacology and molecular docking, this research suggests that Sanhe Decoction may exert "one approach, multiple diseases" potential for CP/CPPS and BPH by:

leveraging key bioactives (quercetin, kaempferol, nootkatone, stigmasterol, isorhamnetin)

engaging hub targets (TP53, SRC, AKT1, ESR1, STAT3)

modulating major pathways (notably AGE‑RAGE and PI3K‑AKT), consistent with inflammation, oxidative stress, endocrine response, and tissue remodeling biology

showing favorable docking interactions (binding energies < −5.0 kcal/mol across core pairs)

For developers of herbal dietary supplements, the value is a coherent mechanistic map that can inform ingredient selection, formulation logic, and next-step validation studies-while staying grounded in what the evidence does and does not prove.